Specialty Areas:
Oligonucleotide-based therapeutic strategies for lung diseases. Delivery of therapeutic oligonucleotides to the lung and other non-hepatic organs. Targeting of therapeutic molecules to the airway epithelium. Regulation of mucin secretion in lung diseases.
Research Focus:
Dr. Kreda’s laboratory studies mechanisms of delivery of therapeutic molecules in the lung. The main goal is to develop novel and efficient delivery strategies of therapeutic nucleic acids in obstructive lung diseases. The Kreda laboratory is currently involved in designing an efficacious oligonucleotide-based therapeutic approach to correct cystic fibrosis mutations in patients resilient to modulator therapies () and orphan mutations that cause primary ciliary dyskinesia (PCD). The PCD studies have recently received funding from the Eshelman Institute for Innovation (see the following links: Silvia M. Kreda to Study Novel Therapeutic Strategy for Primary Ciliary DyskinesiaÌý²¹²Ô»å [in the 2022 tab]) and NC TraCS (see the following links: and Kreda, Leigh, & Ostrowski Selected for SOM Translational Team Science Award). The laboratory uses state-of-the art technologies and patient-oriented models for precision and personalized medicine approaches.
Dr. Kreda’s research focuses also on identifying signaling molecules/pathways that regulate airway mucin secretion. The main goal is to uncover potential targets of clinical interest to control abnormal luminal mucus accumulation in lung diseases. Her laboratory has developed and optimized in vitro and in vivo models of lung diseases with excessive mucus production and quantitative assays for therapeutic drug testing and evaluation of mucin production in airway epithelia.
Dr. Kreda’s laboratory and scientific studies are fully funded by competitive grants from different sources including the National Institutes of Health (NIH), , NCTraCS (the NIH CTSA at ºÚÁÏÍø-CH), Eshelman Institute for Innovation, Initos Pharmaceuticals, AstraZeneca, and Forest Research Institute (now AstraZeneca). Her lab has successful collaborations with scientists from academic and pharmaceutical institutions to develop and test novel drugs for their potential therapeutic use in obstructive lung diseases. For more information contact Dr. Kreda.
Chronology:
- Silvia M. Kreda is a faculty member of the Marsico Lung Institute/Cystic Fibrosis Center; an Associate Professor in the Department of MedicineÌý²¹²Ô»å the Department of Biochemistry and Biophysics.
- 1994 IRTA fellow at NIEHS, RTP NC
- 1992 Post Doctorate, University of North Carolina at Chapel Hill
- 1992 Ph.D., University of Buenos Aires, Argentina
- 1987 M.S., University of Buenos Aires, Argentina
- 1986 Pharm D., R.Ph., University of Buenos Aires, Argentina
- 1984 B.S., University of Buenos Aires, Argentina
Selected Publications:
For further publications, please click here:
- Oeler KJ, Blackmon RL, Kreda SM, Robinson T, Ghelardini M, Chapman BS, Tracy J, Hill DB, Oldenburg AL. . J Biomed Opt. 2024 Apr;29(4):046004. doi: 10.1117/1.JBO.29.4.046004. PMID: 38690122; PMCID: PMC11060333.
- Kreda S. . Curr Opin Pharmacol. 2022 Oct;66:102271. doi: 10.1016/j.coph.2022.102271. PMID: 35988291.
- Dang Y, van Heusden C, Nickerson V, Chung F, Wang Y, Quinney NL, Gentzsch M, Randell SH, Moulton HM, Kole R, Ni A, Juliano RL, Kreda SM. . Nucleic Acids Res. 2021 Jun 21;49(11):6100-6113. doi: 10.1093/nar/gkab488. PMID: 34107015; PMCID: PMC8216463.
- Jaramillo, AM; Piccotti, L; Velasco, WV; Delgado, ASH; Azzegagh, Z; Chung, F; Nazeer, U; Farooq, J; Brenner, J; Parker-Thornburg, J; Scott, BL; Evans, CM; Adachi, R; Burns, AR; Kreda, SM; Tuvim, MJ; Dickey, BF. . JCI Insight.2019 Mar 21;4(6):e124815. PMID: 30721150; PMCID: PMC6483006.
- Wang, L; Ariyarathna, Y; Ming, X; Yang, B; James, LI; Kreda, SM; Porter, M; Janzen, W; Juliano, RL. ACS Chem Biol. 2017 Aug 18;12(8):1999-2007. PMID: 28703575; PMCID: PMC5662188
- Blackmon, RL; Kreda, SM; Sears, PR; Chapman, BS; Hill, DB; Tracy, JB; Ostrowski, LE; Oldenburg, AL. Nanoscale. 2017 Apr 13;9(15):4907-4917. PMID: 28358158; PMCID: PMC5473168
- Jones, L; Moussa, L; Fulcher, L; Yunxiang, Z; Hudson, E; O’Neal, WK; Randell, SH; Lazarowski, ER; Boucher RC; Kreda, SM. J Physiol. 2012 Feb 1;590(3):545-62. PMID: 22144578; PMCID: PMC3379700
- Kreda, SM; Davis, CW; Rose, MC. Cold Spring Harb Perspect Med. 2012 Sep 1;2(9):a009589. doi: 10.1101/cshperspect.a009589. Review. PMID: 22951447; PMCID: PMC3426818
- Kreda, SM; Vidal-Seminario, L; van Heusden, CA; O’Neal, WK; Jones, L; Boucher, RC; Lazarowski, ER. J Physiol. 2010 Jun 15;588(Pt 12):2255-67. PMID: 20421285; PMCID: PMC2911224
- Kreda, SM; Okada, SF; van Heusden, CA; O’neal, W; Gabriel, S; Abdullah, L; Davis, CW; Boucher, RC; Lazarowski, ER. J Physiol. 2007 Oct 1;584(Pt 1):245-59. PMID: 17656429; PMCID: PMC2277076
- Kreda, SM; Mall, M; Mengos, A; Rochelle, L; Yankaskas, J; Riordan, JR; Boucher, RC. . Mol Biol Cell. 2005 May;16(5):2154-67. PMID: 15716351; PMCID: PMC1087225
- Kreda, SM; Pickles, RJ; Lazarowski, E; Boucher, RC. Nat Biotechnol. 2000 Jun;18(6):635-40. PMID: 10835601.
![]() |
![]() |
![]() |
---|---|---|
Kreda et al, 2001 | Kreda et al, 2004 | Kreda et al, 2005 |
![]() |
![]() |
![]() |
Okada et al, 2006 | Kreda et al, 2007 | Mall et al, 2008 |
![]() |
||
Kreda et al, 2008 |
Members of Dr. Kreda’s lab:






Silvia (front, kneeling) walking with her certified therapy dog, Whiskey, and CF Center colleagues during the annual Chapel Hill Great Strides walk to raise awareness and funds for Cystic Fibrosis research.
And there’s a new rescue dog in the Kreda-Parker family! Please meet Echo Parker at this link.